Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Neos Therapeutics Inc. NEOS

Healthcare Drug Manufacturers - Major
Neos Therapeutics Inc is a pharmaceutical company, engaged in the development, manufacture, and commercialization of products for the treatment of attention deficit hyperactivity disorder (ADHD) using its drug delivery technologies. The product portfolio of the company includes Methylphenidate XR-ODT and Amphetamine XR oral suspension commonly prescribed medicine for the treatment of ADHD. In... see more

Recent & Breaking News (NDAQ:NEOS)

Neos Therapeutics to Host Second Quarter 2016 Financial Results Conference Call on August 11, 2016

GlobeNewswire August 2, 2016

Neos Therapeutics Announces Successful Completion of Bioequivalence Bridging Study for Cotempla XR-ODT™ (Methylphenidate Extended-Release Orally Disintegrating Tablet)

GlobeNewswire July 28, 2016

Neos Therapeutics CEO to Present at JMP Securities Life Sciences Conference on June 21, 2016

GlobeNewswire June 14, 2016

Colliers International Increases Semi-Annual Dividend on Common Shares to $0.05

GlobeNewswire May 31, 2016

Neos Therapeutics Appoints Juergen Martens as Chief Technology and Operations Officer

GlobeNewswire May 31, 2016

Neos Therapeutics CEO to Present at 2016 UBS Healthcare Conference on May 24, 2016

GlobeNewswire May 17, 2016

Neos Therapeutics Announces Closing of $60 Million Term Debt Financing and First Quarter 2016 Financial Results

GlobeNewswire May 16, 2016

Neos Therapeutics Announces U.S. Launch of Adzenys XR-ODT™ (Amphetamine Extended-Release Orally Disintegrating Tablet) for the Treatment of ADHD in Patients Six Years and Older

GlobeNewswire May 16, 2016

Neos Therapeutics to Host First Quarter 2016 Financial Results Conference Call on May 16, 2016

GlobeNewswire May 5, 2016

Neos Therapeutics Announces Fourth Quarter and Full Year 2015 Financial Results

GlobeNewswire March 17, 2016

Neos Therapeutics Announces Date of Fourth Quarter and 2015 Fiscal Year Financial Results

GlobeNewswire March 8, 2016

Neos Therapeutics to Present at Upcoming Investor Conferences

Press Releases February 16, 2016

Neos Therapeutics Announces FDA Approval of Adzenys XR-ODT(TM) (Amphetamine Extended-Release Orally Disintegrating Tablet) for the Treatment of ADHD in Patients 6 Years and Older

GlobeNewswire January 27, 2016

How it All Plays Out - Free Research Reports on RTI Surgical, Neos Therapeutics, Uranium Energy and Paratek Pharmaceuticals

Accesswire December 17, 2015

Neos Therapeutics to Present at Stifel Healthcare Conference on November 18, 2015

GlobeNewswire November 11, 2015

Neos Therapeutics Receives Complete Response Letter From the FDA for Cotempla XR-ODT

GlobeNewswire November 10, 2015

Neos Therapeutics Presents Data for Investigational ADHD Treatment Cotempla XR-ODT at AACAP's 62nd Annual Meeting

GlobeNewswire October 30, 2015

IMPORTANT INVESTOR NOTICE: Khang & Khang LLP Announces an Investigation of Claims Against Neos Therapeutics, Inc. and Advises Shareholders to Contact the Firm

Business Wire October 20, 2015

EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Neos Therapeutics, Inc. - NEOS

Business Wire October 20, 2015

IMPORTANT INVESTOR ALERT: Goldberg Law PC Announces An Investigation Of Claims Against Neos Therapeutics, Inc. And Encourages Investors To Contact The Firm

Business Wire October 20, 2015